Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab treatment extension study in multiple myeloma
2023-507180-19-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in multiple myeloma (MM), sponsored by Sanofi. Primary endpoint: Number of participants with treatment-emergent adverse events. Planned start Apr 2023; status: authorised.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-507180-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507180-19-00.